Study of Erlotinib in Combination With Dasatinib

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00895128
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib Hydrochloride — DRUG
    Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
  • Dasatinib — DRUG
    Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.

Study Details

The goal of this clinical research study is to find the highest tolerable dose of Tarceva (erlotinib hydrochloride) that can be given in combination with Sprycel (dasatinib). The safety of this drug combination will also be studied.

Key Dates

First listed
May 8, 2009
Start date
Apr 30, 2009
Status verified
Jul 2015
Primary completion
Jul 31, 2015

Study Design

Enrollment
65 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib + Dasatinib
    Erlotinib starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients. Dasatinib starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.

Primary Outcome Measure

Response Rate [ Time Frame: Response Evaluation after two 28-day cycles. ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies